IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the "Company” or "Tarsus”) today announced the commencement of an underwritten public offering of $100.0 ...

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public ...

A new report on the state of birds in the United States has an urgent warning: bird populations across nearly every habitat are declining, with about one-third of U.S. bird species in critical ...

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the "Company” or "Tarsus”) today announced the pricing of an upsized underwritten public offering of ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

Share on Pinterest A recent CDC MMWR report shows three new asymptomatic human cases of bird flu, suggesting the virus may be slowly spreading. Johanna Moya/Getty Images A growing bird flu ...

IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2024 ...

Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $62.00. The company’s shares closed yesterday at $45.54.

(RTTNews) - Tarsus Pharmaceuticals, Inc (TARS) released Loss for fourth quarter that decreased from last year and beat the Street estimates. The company's earnings totaled -$23.113 million ...